The research and production company Generium has developed a nasal form of the Russian CORONAVIRUS vaccine Sputnik V and has applied for clinical trials of the drug. This was told to TASS by the company's CEO Daniil Talyansky.
“We have made an intranasal form of the vaccine that is simply injected into the nose. it is much more mildly tolerated than a conventional vaccine,” Talyansky said, noting that the effectiveness of the new drug corresponds to the injectable Sputnik V.
According to the HEAD of Generium, the company will be allowed to register the vaccine in six to eight months.
Gunzburg announces clinical trials for nasal covid vaccine Society
Since October 2020, Generium has been one of the manufacturers of the traditional Sputnik V form used for intramuscular injections.